185 related articles for article (PubMed ID: 18952077)
1. Invariant chain+ N2a neuroblastoma cells stably expressing the class II MHC transactivator CIITA fail to stimulate anti-tumor immunity.
Rickard S; Ono SJ
Exp Mol Pathol; 2008 Dec; 85(3):147-54. PubMed ID: 18952077
[TBL] [Abstract][Full Text] [Related]
2. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
3. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
[TBL] [Abstract][Full Text] [Related]
4. Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth.
Martin BK; Frelinger JG; Ting JP
J Immunol; 1999 Jun; 162(11):6663-70. PubMed ID: 10352284
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription Implication of CIITA in tumor and metastasis development.
Shi B; Vinyals A; Alia P; Broceño C; Chen F; Adrover M; Gelpi C; Price JE; Fabra A
Int J Biochem Cell Biol; 2006; 38(4):544-62. PubMed ID: 16343978
[TBL] [Abstract][Full Text] [Related]
6. A CIITA-independent pathway that promotes expression of endogenous rather than exogenous peptides in immune-privileged sites.
Arancibia-Cárcamo CV; Osawa H; Arnett HA; Háskova Z; George AJ; Ono SJ; Ting JP; Streilein JW
Eur J Immunol; 2004 Feb; 34(2):471-80. PubMed ID: 14768052
[TBL] [Abstract][Full Text] [Related]
7. CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells.
Meissner M; Whiteside TL; Kaufmann R; Seliger B
Arch Dermatol Res; 2009 Feb; 301(2):189-93. PubMed ID: 19104823
[TBL] [Abstract][Full Text] [Related]
8. Class II transactivator-mediated regulation of major histocompatibility complex class II antigen expression is important for hematopoietic progenitor cell suppression by chemokines and iron-binding proteins.
Broxmeyer HE; Cooper S; Hangoc G; Chang CH
Exp Hematol; 2006 Aug; 34(8):1078-84. PubMed ID: 16863914
[TBL] [Abstract][Full Text] [Related]
9. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.
Mortara L; Frangione V; Castellani P; De Lerma Barbaro A; Accolla RS
Int Immunol; 2009 Jun; 21(6):655-65. PubMed ID: 19395374
[TBL] [Abstract][Full Text] [Related]
10. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells.
Meazza R; Comes A; Orengo AM; Ferrini S; Accolla RS
Eur J Immunol; 2003 May; 33(5):1183-92. PubMed ID: 12731043
[TBL] [Abstract][Full Text] [Related]
11. MHC class II biosynthesis by activated rat CD4+ T cells: development of repression in vitro and modulation by APC-derived signals.
Mannie MD; Dawkins JG; Walker MR; Clayson BA; Patel DM
Cell Immunol; 2004 Jul; 230(1):33-43. PubMed ID: 15541717
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N
J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831
[TBL] [Abstract][Full Text] [Related]
14. T cell expression of CIITA represses Th1 immunity.
Park WS; Bae Y; Chung DH; Choi YL; Kim BK; Sung YC; Choi EY; Park SH; Jung KC
Int Immunol; 2004 Oct; 16(10):1355-64. PubMed ID: 15351782
[TBL] [Abstract][Full Text] [Related]
15. Collagen and major histocompatibility class II expression in mesenchymal cells from CIITA hypomorphic mice.
Xu Y; McDonald J; Perloff E; Butticè G; Schreiber BM; Smith BD
Mol Immunol; 2007 Mar; 44(7):1709-21. PubMed ID: 16982097
[TBL] [Abstract][Full Text] [Related]
16. Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice.
Jabrane-Ferrat N; Campbell MJ; Esserman LJ; Peterlin BM
Cancer Gene Ther; 2006 Nov; 13(11):1002-10. PubMed ID: 16841083
[TBL] [Abstract][Full Text] [Related]
17. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
[TBL] [Abstract][Full Text] [Related]
18. Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor.
Mueller RB; Skapenko A; Grunke M; Wendler J; Stuhlmuller B; Kalden JR; Schulze-Koops H
Arthritis Rheum; 2005 Feb; 52(2):451-60. PubMed ID: 15692975
[TBL] [Abstract][Full Text] [Related]
19. The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in myelomonocytic cells.
De Lerma Barbaro A; Procopio FA; Mortara L; Tosi G; Accolla RS
Eur J Immunol; 2005 Feb; 35(2):603-11. PubMed ID: 15627980
[TBL] [Abstract][Full Text] [Related]
20. Regulation of the class II and class I MHC pathways in human THP-1 monocytic cells by interleukin-27.
Feng XM; Liu N; Yang SG; Hu LY; Chen XL; Fang ZH; Ren Q; Lu SH; Liu B; Han ZC
Biochem Biophys Res Commun; 2008 Mar; 367(3):553-9. PubMed ID: 18178151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
